This article explores how CRISPR treatment is reshaping medical and social views on Trisomy 21, revolutionising management approaches. 

Trisomy 21, the most common form of Down Syndrome that occurs in 1in 700 live births, evidently presses several medical issues including congenital heart defects (40-50% of DS children), gastrointestinal anomalies, autoimmune conditions, increased risks of diverse leukaemia, thyroid disorders, hearing loss (75% of DS children experience), vision loss, cognitive impairment, early onset of dementia, among others.    

In 1959, French geneticist Jérôme Lejeune uncovered a pivotal discovery: Down Syndrome (Trisomy 21) was caused by the presence of an extra copy of chromosome 21 due to random error (nondisjunction) during meiosis, leading to excess genetic material that disrupts normal cellular function and development. Over 6 decades since this revelation, primary approaches to this most common chromosomal disorder include therapies to address symptoms, early interventions applied to maximise development, along with social inclusions to improve quality of life for those who are affected. This showcases despite the immense medical advances in understanding the molecular basis of the condition, the extra chromosome remained untouchable. Such stark reality established a clear boundary in medicine, undermining prospects for a definitive cure.

This foundational truth has just been challenged through a quiet revolution, not in a clinic but in a petri dish. In a groundbreaking study published by PNAS Nexus in February 2025, Dr. Hashizume and his colleagues performed allele specific targeted removal of an entire extra chromosome in laboratory grown cells while leaving the pair still intact with the application of CRISPR-Cas9 gene editing technology, an achievement that once was thought impossible. Although not demonstrated in human embryos or living people, this approach corrects the underlying genetic imbalance, reverses cellular abnormalities and restores normal gene expression patterns. 

The innovation of this molecular strategy heavily relies on the crucial insight that although three copies of chromosome 21 look nearly identical, they contain subtle genetic differences that can be exploited. Such manipulation is evident in research employing Haplotype Phasing, where researchers “fingerprint” each chromosome to identify which ones are from the Mother (M1 & M2) and the Father(P). Through this distinction, the CRISPR-Cas 9 was designed to recognise and cut only the M2 chromosome as it was the safest extra chromosome to remove. This precision makes this approach especially revolutionary as it is unlike previous “allele non specific” (ANS) methods that indiscriminately cut all three chromosomes, previously noted to overwhelm the cell’s repair mechanisms and inflict up to 87.3% of cell death, and instead achieves a 57% higher cell survival rate and higher chromosome elimination rates (13.1% for AS v.s 6% for ANS).

Removal of the extra chromosome (M2) leading identification similarly works as a molecular surgery of precision guided scissors where Cas-9 protein in the CRISPR-Cas 9 creates 13 strategic cuts along M2 and shreds it into fragments, making it almost impossible for cell repair from damage. To ensure this effect remains permanent, researchers temporarily suppress key DNA repair genes (POLQ and LIG4) and block cell repair mechanisms (NHEJ and MMEJ pathways) with siRNA (a silencing molecule), preventing the cell from stitching the broken chromosome back together. During cell division, these chromosome fragments fail to properly segregate and eventually get lost which effectively removes chromosome 21 in the long term.

While this marks a profound step in the scientific effort to understand and potentially correct genetic disorders, it simultaneously raises social controversies on ethics and the boundaries of medical intervention. Some view this research as a hopeful leap towards reducing medical burdens and improving the quality of life for individuals with Down Syndrome, while others fear this procedure could reinforce ableist ideas that lives with disabilities are less valuable. Ethicists including S. Benton emphasises that DS is not merely a medical condition but also a distinct human identity into society’s diversity. Questions about consent, genetic selection and social acceptance further complicate the issue when they come into play, especially if such procedures were ever considered for embryos.

As science edges closer to rewriting the human genome, the world finds itself standing at a crossroads between discovery and responsibility. The same CRISPR technology that could one day erase Trisomy 21 also challenges us to reconsider what it truly means to cure rather than to change. For now, Dr. Hashizume’s work represents more than a genetic milestone, it’s a moment that asks society to reflect on its values. Can we celebrate such progress without losing sight of the humanity it seeks to help? The answer, much like science itself, is still unfolding.

Up Next